NeuroMetrix Inc
NASDAQ:NURO
Intrinsic Value
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. [ Read More ]
The intrinsic value of one NURO stock under the Base Case scenario is 9.26 USD. Compared to the current market price of 4.25 USD, NeuroMetrix Inc is Undervalued by 54%.
Valuation Backtest
NeuroMetrix Inc
Run backtest to discover the historical profit from buying and selling NURO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of NeuroMetrix Inc's business.
What risks and challenges
does NeuroMetrix Inc face in the near future?
Summarize the latest earnings report
of NeuroMetrix Inc.
Provide P/E
for NeuroMetrix Inc and its competitors.
Balance Sheet Decomposition
NeuroMetrix Inc
Current Assets | 20.7m |
Cash & Short-Term Investments | 17.6m |
Receivables | 610k |
Other Current Assets | 2.5m |
Non-Current Assets | 580k |
PP&E | 550k |
Other Non-Current Assets | 30k |
Current Liabilities | 1.3m |
Accounts Payable | 230k |
Accrued Liabilities | 1m |
Non-Current Liabilities | 120k |
Other Non-Current Liabilities | 120k |
Earnings Waterfall
NeuroMetrix Inc
Revenue
|
6.4m
USD
|
Cost of Revenue
|
-2.1m
USD
|
Gross Profit
|
4.3m
USD
|
Operating Expenses
|
-10.5m
USD
|
Operating Income
|
-6.2m
USD
|
Other Expenses
|
580k
USD
|
Net Income
|
-5.6m
USD
|
Free Cash Flow Analysis
NeuroMetrix Inc
What is Free Cash Flow?
NURO Profitability Score
Profitability Due Diligence
NeuroMetrix Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
NeuroMetrix Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
NURO Solvency Score
Solvency Due Diligence
NeuroMetrix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
NeuroMetrix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NURO Price Targets Summary
NeuroMetrix Inc
Ownership
NURO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NURO Price
NeuroMetrix Inc
Average Annual Return | -24.53% |
Standard Deviation of Annual Returns | 59.03% |
Max Drawdown | -99% |
Market Capitalization | 8.4m USD |
Shares Outstanding | 1 986 540 |
Percentage of Shares Shorted | 2.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2004-07-22. The firm is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The company has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.
Contact
IPO
Employees
Officers
The intrinsic value of one NURO stock under the Base Case scenario is 9.26 USD.
Compared to the current market price of 4.25 USD, NeuroMetrix Inc is Undervalued by 54%.